Skin care advice to patients with multiple sclerosis on Fingolimod treatment at increased risk of skin malignancy-room for improvement?

Abstract

Fingolimod is used to treat relapsing-remitting multiple sclerosis. It has an immunosuppressive effect that predisposes to skin malignancies. The Summary of Product Characteristics recommends that persons receiving Fingolimod be educated regarding photoprotection and vigilance of skin lesions and should undergo a dermatological evaluation at initiation of treatment and 6-12 monthly thereafter. The incidence of keratinocytic carcinomas in those on long-term immunosuppression following solid organ transplantation is declining. This trend coincided with temporal changes in immunosuppressive protocols and the introduction of skin cancer prevention programmes suggesting that the risk of developing these malignancies may be mitigated by the provision of education to patients amongst other measures. The aim of our study was to assess if health care professionals are explaining skin advice and documenting the discussion when prescribing Fingolimod in a University Hospital outpatient setting. Clinical records of consecutive patients on Fingolimod were reviewed. Data on demographics, documented provision of advice on skin protection and who provided the advice was collected. Fifty patients with multiple sclerosis were identified. Median age was 40.5 years (range 25-63). Forty-two were female (42/50, 84%). Provision of advice regarding skin protection was documented in 20% (10/50). This was provided by nurse specialists in 14% (7/50), doctors in 10% (5/50) and both in 4% (2/50). The risk of developing skin cancers can be reduced by the adoption of simple preventative measures; patients on Fingolimod are at an increased risk of developing these cancers. This study demonstrates a need for improvement in the documentation of advice around skin protection.

• Authors: Lisa O'Higgins, Maria Gaughan, Christopher McGuigan, Aoife Lally
• Journal: Irish journal of medical science (Ir J Med Sci) Vol. 191 Issue 4 Pg. 1683-1685 (Aug 2022) ISSN: 1863-4362 [Electronic] Ireland
• PMID: 34495479 (Publication Type: Letter)
• Copyright: © 2021. Royal Academy of Medicine in Ireland.

Chemical References

• Immunosuppressive Agents
• Fingolimod Hydrochloride

Topics

• Adult
• Female
• Fingolimod Hydrochloride (adverse effects)
• Humans
• Immunosuppressive Agents (adverse effects)
• Male
• Middle Aged
• Multiple Sclerosis (drug therapy)
• Multiple Sclerosis, Relapsing-Remitting (drug therapy)
• Skin Care
• Skin Neoplasms (epidemiology, prevention & control)